Roy Winston is Chief Medical Officer at Pacira BioSciences, Inc. (PCRX). They have made 9 open-market trades across 1 company since 2019, most recently 2023-08-02.
CIK 0001751757
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $91K since 2020, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PCRX | 52,440 | $1.9M |
Shares reported on the most recent Form 4, priced at the 2023-08-04 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PCRX | SELL | 2023-08-02 | 2023-08-04 | $34.88 | $18K | -6.3% | -12.0% | -26.1% |
| PCRX | SELL | 2023-06-06 | 2023-06-07 | $38.42 | $279K | +9.4% | +1.4% | -7.0% |
| PCRX | SELL | 2022-08-03 | 2022-08-05 | $55.70 | $27K | -0.7% | -12.5% | -15.3% |
| PCRX | SELL | 2022-06-06 | 2022-06-08 | $61.31 | $1.9M | -9.5% | -2.7% | -12.5% |
| PCRX | SELL | 2021-06-04 | 2021-06-08 | $61.04 | $278K | -1.9% | -7.4% | -7.2% |
| PCRX | SELL | 2021-03-31 | 2021-04-02 | $70.57 | $3.1M | -2.1% | -13.3% | -15.4% |
| PCRX | SELL | 2020-11-13 | 2020-11-17 | $62.00 | $310K | -5.8% | -6.4% | +15.5% |
| PCRX | BUY | 2020-03-11 | 2020-03-12 | $36.50 | $91K | -14.4% | -1.3% | +32.2% |
| PCRX | SELL | 2019-06-04 | 2019-06-06 | $42.91 | $31K | +3.1% | +1.9% | -13.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.